

# COVID-19 VACCINATION SINOPHARM

The WHO strategic Advisory Group of Experts (SAGE) on immunization has issued interim recommendations for the use of the inactivated COVID-19 vaccine BIBP developed by Sinopharm/China National Pharmaceutical Group. Date approval by WHO for Covid-19 :On 7May 2021 Vaccine Type : Inactivated

## Vaccination doses and schedule :

Sinopharm COVID-19 vaccine is recommended for people aged 18 and above.the vaccine gives as 2 doses (0.5ml) intramuscularly. WHO recommended interval 3-4 weeks between the first and second dose.

## Technology used :

technology used to produce an inactivated virus vaccine is considered safe since this traditional type of vaccine, e.g. some inactivated flu vaccines has been used for a long time.

## Efficacy & studies:

A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose.

Efficacy in Delta variant : in pregnancy, or in people aged 60 years and above. Women were underrepresented in the trial. The median duration of follow-up available at the time of evidence review was 112 days. In addition, the efficacy of COVID-19 vaccines might widely vary against different variants. (Information is as of 14 May 2021).

